Research & Education

The evolving role of PD-1/PD-L1 inhibitors in the clinical management of non-small cell lung cancer

Wednesday, June 10, 2015 9 p.m. ET - Recording Available

 

   

Edward Garon, MD
Associate Professor
Director: Thoracic Oncology Program
David Geffen School of Medicine at UCLA

Ramaswamy Govindan, MD - Program Chair
Co-Director, Section of Medical Oncology
Professor of Medicine
Division of Oncology
Washington University School of Medicine

Name of Reviewer(s): 

              

Fred Hirsch, MD, PhD –Speakers Bureau/Advisory Board: Astrazeneca, Genentech, BMS, Lilly and Abbvie.

Name of Planner(s): 

 

      Deb Whippen-Nothing to Disclose

 

Name of Activity: 

 

The evolving role of PD-1/PD-L1 inhibitors in the clinical management of non-small cell lung cancer

Date of Activity:

 

06/10/2015

Faculty/Speaker(s):

 

Edward Garon, MD - Research Grant from: Astrazeneca, Bristol -Myers Squibb, Eli Lilly, Genentech, Merck, Novartis, Pfizer and Puma Biotechnology.

Consultant for: Eli Lilly, Bristo-Myers Squibb, Clovis, Oncology, Merck and Novartis.

OFF LABEL DRUGS: All discussion of PD-1 or PD-L1 inhibitors with the exception of nivolumad in previously treated squamous cell lung cancer is off label.

Ramaswamy Govindan, MD - Program Chair/Moderator-Pfizer: Advisory Board, Celgene: Advisory Board, AztraZeneca: Advisory Board, INC Research: Consulting, AbbVie: Consulting, Advisory Board and Honorarium, MSK: Advisory Board.

Type of Activity: 

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?

 Yes  

If yes, please list: Unrestricted  grant from: Genentech, Celgene and Bristol-Meyers Squibb.

IASLC continues the Lung Cancer  Series in 2015 with this LIVE WEBINAR featuring Dr. Edward Garon.

This presentation will inform the participant about emerging data regarding inhibitors of PD-1 and PD-L1. Agents discussed will include those that are FDA approved for non-small cell lung cancer, as well as those for which there is data available but no current approval. Topics to be addressed will include data with respect to efficacy, safety, and proposed approaches to select patients most likely to have clinical benefit with these agents.

After viewing this program attendees will:

  • Describe and anticipate toxicities with this class of agent, and how to address these toxicities
  • Illustrate familiarity with proposed factors that can assist in selecting patients most likely to benefit from this class of drug, including the strengths of these selection methods as well as their weaknesses
  • Assess whether patients who are receiving these agents are benefiting or have reasonable potential to benefit or should be switched to other treatment modalities.

Following the presentation, there will be ample time for discussion and a question/answer session. Attendees will be able to submit questions and comments to Dr. Garon via internet chat.

DOWNLOAD RECORDING

CME INFORMATION:

Financial/Commercial Relationships DISCLOSURE

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. 

 This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/moderators/peer reviewers et. al. conflicts of interest  were identified, reviewed and resolved from all individuals involved in the development  or able to influence and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.  Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from any of IASLC CME activity presentation.

 

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

 

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

GOAL & PURPOSE

This presentation will inform the participant about emerging data regarding inhibitors of PD-1 and PD-L1. Agents discussed will include those that are FDA approved for non-small cell lung cancer, as well as those for which there is data available but no current approval. Topics to be addressed will include data with respect to efficacy, safety, and proposed approaches to select patients most likely to have clinical benefit with these agents.

TARGET AUDIENCE

 

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

DISCLAMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Thank you for your participation. 

Financial Commercial  Relationships and Conflicts of Interest Policy

IASLC Honorarium Policy

IASLC Financial/Commercial Relationships Agreement (LOA)

IASLC Lung Cancer  webinars will continue throughout 2015. The goal is to hold one program monthly. Participants who complete a pre-and post-test along with an evaluation will receive 1 AMA PRA Category 1 CreditTM for each completed webinar.

If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program. CME credit is only available to attendees of the live webinar.

 

Location Local time Time zone UTC offset
New York (U.S.A. - New York) Wednesday, June 10, 2015 at 9:00:00 PM EDT UTC-4 hours
Denver (U.S.A. - Colorado) Wednesday, June 10, 2015 at 7:00:00 PM MDT UTC-6 hours
London (United Kingdom - England) Thursday, June 11, 2015 at 2:00:00 AM BST UTC+1 hour
Rome (Italy) Thursday, June 11, 2015 at 3:00:00 AM CEST UTC+2 hours
New Delhi (India - Delhi) Thursday, June 11, 2015 at 6:30:00 AM IST UTC+5:30 hours
Moscow (Russia) Thursday, June 11, 2015 at 4:00:00 AM MSK UTC+3 hours
Shanghai (China - Shanghai Municipality) Thursday, June 11, 2015 at 9:00:00 AM CST UTC+8 hours
Sydney (Australia - New South Wales) Thursday, June 11, 2015 at 11:00:00 AM AEST UTC+10 hours
Tokyo (Japan) Thursday, June 11, 2015 at 10:00:00 AM JST UTC+9 hours
Corresponding UTC (GMT) Thursday, June 11, 2015 at 01:00:00    

How to use the Time Zone Converter

This series is supported in part by unrestricted educational grants provided by Bristol-Myers Squibb Co., Celgene and Genentech